Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Rome – page 37

2 244 clinical trials in Rome, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Rome at a glance
2 244
clinical trials
  • Research sites15
Type of trial
Recruitment status
Quick filters

2 244 trials in Rome

Open in trial search

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bicara Therapeutics Inc.

Study of SAR444336 in Adults with Microscopic Colitis Who Achieved Clinical Remission with Budesonide Treatment

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:SAR444336
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione GONO G.I.

Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Study of lurbinectedin and irinotecan in adults and young adults with advanced desmoplastic small round cell tumor

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lurbinectedin
  • Sponsor:Italian Sarcoma Group

Study of TYRA-300-B01 tablets in patients with low grade, intermediate risk non-muscle invasive bladder cancer who have FGFR3 gene changes

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:TYRA-300-B01
  • Sponsor:Tyra Biosciences Inc.

Study comparing cetuximab with chemotherapy versus bevacizumab with chemotherapy in patients with advanced colorectal cancer who have wild-type RAS and right-sided tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione GONO G.I.

Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Study of NX-5948 in adults with relapsed or resistant chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received BTK inhibitor and BCL-2 inhibitor treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:NX-5948
  • Sponsor:Nurix Therapeutics Inc.

Study of efgartigimod given by IV infusion in adolescents aged 12-17 years with chronic immune thrombocytopenia

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic bone marrow-derived mesenchymal stromal cells, from selected donors
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda

Study of RO7837195 injection compared to placebo to treat moderate to severe ulcerative colitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:RO7837195
  • Sponsor:Genentech Inc.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Rome

What the registry says about research in the country

01 Hematology and Blood Cancers

In Roma, a large share of recruiting studies focuses on hematologic malignancies and related blood disorders, with research spanning leukemia, lymphoma, myelodysplastic syndromes, and myelofibrosis. These trials are mainly designed to test new treatment combinations, improve disease control, and deepen understanding of measurable disease response.

  • Acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myeloid leukemia
  • Follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and marginal zone lymphoma
  • Myelodysplastic syndromes, myelofibrosis, anemia linked to marrow disease, and transplant-related settings
  • Studies often aim to improve remission rates, reduce residual disease, or extend survival

This is a strong area of research activity across multiple research sites in the city, reflecting a broad effort to refine modern blood cancer care.

02 Solid Tumors and Breast Cancer

Another major focus is neoplasms, especially breast cancer, colorectal cancer, head and neck cancer, and other advanced solid tumors. The trials are generally aimed at improving survival, increasing response to treatment, and identifying more effective therapeutic sequences.

  • Early and metastatic breast cancer, including hormone receptor-positive and triple-negative disease
  • Metastatic colorectal cancer, rectal cancer, and high-risk colon cancer
  • Recurrent or metastatic head and neck squamous cell carcinoma and other difficult-to-treat tumors
  • Research commonly tests new drug combinations and personalized treatment strategies

Several studies also explore biomarkers and treatment adaptation to better match therapy with tumor biology.

03 Immunology, Inflammation, and Autoimmune Disease

Immune system diseases and chronic inflammatory conditions form another important part of the trial landscape. Research in this area includes autoimmune, allergic, and inflammatory disorders, with a focus on easing symptoms, maintaining disease control, and improving long-term safety.

  • Psoriatic arthritis, plaque psoriasis, and atopic dermatitis
  • Crohn’s disease and chronic inflammatory demyelinating polyneuropathy
  • Hereditary angioedema and inflammatory cardiomyopathy
  • Many trials are evaluating better symptom control and sustained treatment benefit

These studies highlight a growing interest in targeted immune-modulating therapies for both skin and systemic inflammatory disease.

04 Cardiovascular Research

Cardiovascular diseases are also well represented, particularly in patients with coronary disease, heart failure-related inflammation, and amyloid-related cardiac conditions. The main goal is to improve safety and clinical outcomes while reducing complications linked to long-term treatment.

  • Atrial fibrillation after PCI and broader antithrombotic treatment questions
  • Inflammatory cardiomyopathy and severe cardiac inflammation
  • Transthyretin cardiac amyloidosis
  • Trials are often assessing better balance between protection from events and bleeding risk

This area combines prevention, treatment optimization, and symptom management for patients with complex heart disease.

05 Neurology and Mental Health

Research in nervous system diseases includes both neurological and neuropsychiatric conditions. The studies aim to improve symptom control, evaluate new treatment options, and support longer-term tolerability in chronic disorders.

  • Psychosis associated with Alzheimer’s disease
  • Chronic inflammatory demyelinating polyneuropathy
  • Trials focus on treatment effectiveness, safety, and sustained control of symptoms

These projects reflect an effort to address conditions that can strongly affect independence and quality of life.

06 Kidney, Metabolic, and Endocrine Disorders

A notable group of studies addresses nutritional and metabolic diseases as well as kidney and hormone-related disorders. The research is aimed at slowing progression, improving biochemical control, and easing treatment burden for chronic conditions.

  • Autosomal dominant polycystic kidney disease and IgA nephropathy
  • Hypoparathyroidism, obesity, and propionic acidemia
  • Trials seek to improve organ function, calcium balance, and metabolic stability
  • Some studies compare existing standards with newer treatment approaches

This field shows a mix of rare-disease research and more common chronic metabolic care.

07 Infectious Disease and Surgery-Related Prevention

Several studies in bacterial infections and mycoses and virus diseases focus on preventing or treating infection, including work in surgical and urinary settings. The purpose is to reduce complications, improve recovery, and support more efficient antibiotic use.

  • Urinary tract infections and postoperative incisional infection prevention
  • HIV treatment optimization in virologically suppressed patients
  • Research also includes strategies for improving infection control after surgery

These trials are clinically practical, with a clear focus on safer care and better patient outcomes.

08 Dermatology and Skin Healing

Skin and connective tissue diseases are represented by studies on chronic inflammatory skin conditions and difficult-to-heal wounds. The main research goal is to improve healing, reduce lesion burden, and strengthen everyday symptom relief.

  • Atopic dermatitis and moderate-to-severe psoriasis
  • Venous leg ulcers and wound bed preparation
  • Studies are testing more effective symptom control and better tissue repair

This area combines dermatologic care with wound-management research relevant to both specialists and patients.

09 Gastroenterology and Digestive System Diseases

Trials in digestive system diseases address inflammatory bowel disease, bile acid diarrhoea, and colorectal conditions. Researchers are working to improve symptom relief, support healing, and refine treatment choices for persistent gastrointestinal problems.

  • Crohn’s disease and bile acid diarrhoea
  • Rectal cancer and colon cancer
  • Some studies examine better disease control and organ-preserving treatment approaches

The work in Roma reflects both common gastrointestinal care and more specialized oncologic research.

10 Rare and Genetic Disorders

A smaller but important portion of the portfolio covers congenital, hereditary, and neonatal diseases, with a focus on rare inherited disorders. These trials aim to improve disease control, support organ preservation, and expand treatment options where choices are limited.

  • Propionic acidemia
  • Hereditary angioedema and autosomal dominant polycystic kidney disease
  • Research often explores new therapies for symptom prevention and long-term disease management

This area is especially relevant for patients living with uncommon conditions that require specialized care.

11 Urology and Genitourinary Cancer

Male and female urogenital diseases appear in studies on urinary tract infections, urothelial cancer, and pregnancy-related complications, alongside cancer-focused work. The goal is generally to improve treatment effectiveness while reducing recurrence or complications.

  • Low-grade upper tract urothelial cancer and urinary tract infections
  • Some studies also involve renal and reproductive health-related conditions
  • Trial aims include better tumor control, infection management, and safer treatment options

These trials add breadth to the city’s research profile beyond hematology and solid tumors.

12 Bone, Muscle, and Joint Disorders

Musculoskeletal diseases are represented through inflammatory joint disease research, especially in conditions that affect daily mobility and function. The studies are mainly designed to ease inflammation, improve function, and compare treatment strategies.

  • Psoriatic arthritis
  • Focus on symptom relief and better control of joint inflammation
  • Comparisons often center on established therapies versus newer targeted approaches

This field complements the broader immune-mediated disease research seen across the city.

13 Analytical, Diagnostic, and Therapeutic Techniques

A smaller set of studies in analytical, diagnostic and therapeutic techniques and equipment supports broader clinical research by improving how conditions are monitored and treated. The emphasis is on practical innovation, better decision-making, and treatment support across multiple disease areas.

  • Research tools that help assess response, safety, or disease burden
  • Technique-focused studies linked to cancer, cardiovascular, and surgical care
  • Purpose is usually to make treatment delivery or evaluation more effective

This work strengthens the overall trial environment by supporting more precise and efficient clinical care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.